CHF Solutions, Inc. Acquires Impedance Technology from Vasamed, Inc.
When appropriate, the company intends to evaluate additional product development and seek additional regulatory clearance before the technology will again be available for commercial use.
“We believe there is an opportunity to leverage this proprietary technology in conjunction with our Aquadex FlexFlow® system by providing clinicians additional hemodynamic information to confidently target how much fluid to remove, manage fluid removal settings, and inform when to stop ultrafiltration,” said
About
Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, the statements regarding the benefits from using the Aquadex FlexFlow, our plans to develop and seek regulatory clearance for a product incorporating the AcQtrac technology, our ability to leverage the AcQtrac technology in connection with our Aquadex FlexFlow system and our ability to demonstrate that the AcQtrac technology will be a useful tool to assist in the management of fluid overloaded patients. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our recently announced strategic realignment, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
CONTACTS:
INVESTORS:
Chief Financial Officer
952-345-4205
ir@chf-solutions.com
-or-
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com
MEDIA
917-885-7378
jabraham@jqapartners.com
Source: CHF Solutions, Inc.